



Committee on Public Health Consequences of Changes in the Cannabis Policy Landscape: Committee Meeting 1

September 15, 2023 National Academy of Sciences 2101 Constitution Ave. NW, Room 250 Washington, DC 20418

## **Public Session Goals:**

• Learn about sponsoring agencies interest in this NASEM study on cannabis policy, learn how the study will compliment other work being done by the sponsoring agencies.

10:00 AM	Purpose of open session and introduction of committee members Steven M. Teutsch, <i>Committee Chair</i>
10:20	CDC perspectives on study scope, background, and objectives Brooke Hoots, Cannabis Strategy Unit Lead, Division of Overdose Prevention, Centers for Disease Control and Prevention
10:45	NIDA perspectives on study scope, background, and objectives Susan Weiss, Director, Division of Extramural Research at the National Institute on Drug Abuse, National Institutes of Health
11:10	NCI perspectives on study scope, background, and objectives Joseph T. Ciccolo, Program Director, Tobacco Control Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute
11:35	NCCIH perspectives on study scope, background, and objectives  David Shurtleff, Deputy Director, Acting Scientific Director, National Center for Complementary and Integrative Health
11:45	FDA perspectives on study scope, background, and objectives Patrick Cournoyer, Senior Science Advisor and Federal Drug Administration Lead for Cannabis Products
11:50	Committee discusses the statement of task with the study sponsors
12:15 PM	Opportunity for public comment on committee's statement of task (must preregister)  1 person per organization, 3-minutes each
1:15	Public Session Adjourns